November 9, 2022

RADICAVA® Oral Suspension Approved in Canada for the Treatment of ALS

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Hiroaki Ueno; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, announced today, that Health Canada has approved RADICAVA® Oral Suspension (edaravone) for the treatment of patients with amyotrophic lateral sclerosis (ALS) on November 8, 2022.

RADICAVA® Oral Suspension contains the same active ingredient as edaravone for intravenous infusion (Japanese product name: Radicut® Injection 30 mg and Radicut® Bag for I.V. Infusion 30 mg) for the treatment of ALS. RADICAVA® Oral Suspension is specifically formulated for patients with ALS and provides a flexible administration option taken orally or via feeding tube.

Prior to this approval, edaravone is solely administered via intravenous infusion. In the U.S., RADICAVA® Oral Suspension (U.S. product name: RADICAVA ORS®) was approved on May 12, 2022, and as of the end of September, approximately 2000 ALS patients have received this product as a new oral treatment option. There is an estimated 3000*1 people living with ALS in Canada and approximately 20,000*2 in the U.S.

MTPC Group is working to further advance its global development in Japan and Switzerland in an effort to provide RADICAVA® Oral Suspension as a new treatment option to patients in these countries.

*1 Benchmarking Survey, Federation of ALS Societies of Canada, 2016.
*2 Arthur KC, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016 Aug;7:12408.

Mitsubishi Chemical Group
Corporate Communications Division
Osaka Corporate Communications Department
Media contacts: [+81] (0)6-6205-5119